Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

被引:106
作者
Perry, PJ
Sanger, T
Beasley, C
机构
[1] UNIV IOWA,COLL PHARM,DIV CLIN PHARM,IOWA CITY,IA 52242
[2] ELI LILLY & CO,INDIANAPOLIS,IN 46285
关键词
D O I
10.1097/00004714-199712000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Olanzapine is an atypical antipsychotic effective in the treatment of-schizophrenic patients. After a 2- to 9-day placebo lead-in, 79 inpatients with schizophrenia according to DSM-III-R criteria were placed on an olanzapine dosage of 10 mg/day or 1 mg/day for up to 6 weeks. Blood samples mere obtained meekly during this period. Receiver operating characteristic curve analyses of Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Syndrome Scale rating scale data suggested a minimum effective therapeutic concentration of 9 ng/ml. Using an intent-to treat analysis, 45% of the patients with olanzapine plasma concentrations greater than or equal to 9.3 ng/mL responded (greater than or equal to 20% decrease in BPRS), whereas only 13% of the patients with concentrations <9.3 ng/mL responde, Use of olanzapine plasma, concentrations of >9 ng/mL as a predictor for treatment response in acutely ill schizophrenic patients is practicable because this therapeutic marker significantly increases the likelihood of a patient responding to olanzapine.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 50 条
[31]   Less is more:: A retrospective investigation of haloperidol dosages in acutely ill schizophrenic patients [J].
Müller, R ;
Kissling, W ;
Kockott, G .
PSYCHIATRISCHE PRAXIS, 2000, 27 (02) :69-73
[32]   CLOZAPINE AND NORCLOZAPINE PLASMA-CONCENTRATIONS AND CLINICAL-RESPONSE OF TREATMENT-REFRACTORY SCHIZOPHRENIC-PATIENTS [J].
PERRY, PJ ;
MILLER, DD ;
ARNDT, SV ;
CADORET, RJ .
AMERICAN JOURNAL OF PSYCHIATRY, 1991, 148 (02) :231-235
[33]   A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients [J].
Breier, A ;
Wright, P ;
Birkett, M ;
David, S ;
Brook, S ;
Meehan, K .
BIOLOGICAL PSYCHIATRY, 2001, 49 (08) :121S-121S
[34]   Plasma olanzapine concentrations in clinical practice: UK experience [J].
Spencer, EP ;
Morgan, PE ;
Flanagan, RJ ;
Taylor, D .
THERAPEUTIC DRUG MONITORING, 2005, 27 (02) :226-227
[35]   Effect of MDR1 genotype on clinical response to risperidone in acutely exacerbated schizophrenic patients [J].
Nakagami, T. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 :255-255
[36]   Impact of voriconazole plasma concentrations on treatment response in critically ill patients [J].
Ruiz, Jesus ;
Gordon, Monica ;
Villarreal, Esther ;
Peruccioni, Marcela ;
Remedios Marques, Maria ;
Luis Poveda-Andres, Jose ;
Castellanos-Ortega, Alvaro ;
Ramirez, Paula .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2019, 44 (04) :572-578
[37]   EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTELY ILL SCHIZOPHRENIC OUTPATIENTS [J].
UCER, E ;
CASEY, P .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1979, 25 (01) :144-149
[38]   POOR NEUROLEPTIC RESPONSE IN ACUTELY EXACERBATED SCHIZOPHRENIC-PATIENTS [J].
SHALEV, A ;
HERMESH, H ;
ROTHBERG, J ;
MUNITZ, H .
ACTA PSYCHIATRICA SCANDINAVICA, 1993, 87 (02) :86-91
[39]   Clinical experience with in travenous levetiracetam in acutely ill patients [J].
Vaysbrot, Maya ;
Bindra, T. ;
Fuentes, B. ;
Spinner, W. D. ;
Kokoszka, A. ;
Miller-Horn, J. ;
Andriola, M. R. .
EPILEPSIA, 2007, 48 :373-374
[40]   Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients [J].
Ansermot, Nicolas ;
Vathanarasa, Harish ;
Ranjbar, Setareh ;
Gholam, Mehdi ;
Crettol, Severine ;
Vandenberghe, Frederik ;
Gamma, Franziska ;
Plessen, Kerstin Jessica ;
von Gunten, Armin ;
Conus, Philippe ;
Eap, Chin B. .
THERAPEUTIC DRUG MONITORING, 2024, 46 (06) :828-836